Monday, June 30, 2025 6/30/2025

Botanical derived progestins and their impact on women's health

Award Number: R01AT008824
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2016
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Botanical derived progestins and their impact on women's health - Botanical dietary supplement use has skyrocketed over the last ten years. One significant portion of this market is herbal supplements targeted toward women, who commonly use them to treat their gynecological ailments, not only for their cost-effective advantage or affordability, but also for their health benefits. Progesterone is an endogenous hormone and synthetic progestins are used therapeutically for a variety of conditions including prevention of uterine hyperplasia, which increases the risk of uterine cancer, uterine bleeding, endometriosis, and prevention of preterm birth. Selective progesterone receptor (PR) modulators are also used in the treatment of prevention of fibroids, which occur in 80% of women. At a national level, treating benign gynecological conditions is expensive, with an annual cost of between $13–$22 billion. Thus, studying alternative therapies that women are already widely consuming is significant. However, a major technological and scientific gap exists: while botanicals are being widely consumed and contain compounds that are relatively safe, these compounds have not been identified or rigorously biologically evaluated, which is an area of emphasis for NCCIH (NOT-AT-21-006) that is specifically addressed in this application. Phytoprogestins need to be identified and studied in order to apply them for safe and effective use in uterine disorders. To address this, our team laid the groundwork for this new subfield of chemodietary prevention through the identification and biological characterization of molecules from dogwood, vitex, red clover, and yucca, as these contained compounds that modified PR signaling. In the current proposal our goal is to identify the structures of compounds in several other commonly consumed botanicals that modify PR signaling so that they can be examined for safety and efficacy in preclinical chemodietary prevention models, including prevention of fibroids, preterm birth and uterine hyperplasia. We aim to test our hypothesis that commonly consumed botanicals used to improve women’s health contain compounds that regulate PR signaling via three integrated aims. We will 1) Isolate and characterize the structures of phytoprogestin natural products from validated plant material through use of a cell-based PRE- luciferase assays and measure active compound abundance in commercial products; 2) Confirm that isolated compounds bind to a receptor, determine if they function as agonists, antagonists, or potentiators, determine if they modify off-target receptors, and refine their genome-wide transcriptional action using RNA seq; and 3) Confirm that chemodietary prevention using phytoprogestin-containing botanicals reduces preterm birth, uterine hyperplasia or blunts fibroid growth. Since little is known about phytoprogestin content and their associated biological activities from botanicals widely consumed by women, this study presents a profound opportunity to inform the treatment of gynecologic disorders and increase awareness in those consuming these botanicals already. Further, because women are already consuming these botanicals, studies should be conducted to understand their progesterone-modifying properties even if synthetic compounds exist.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $359,775 )
2025	2025	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	8	3/17/2025	NON-COMPETING CONTINUATION	$359,775
														Subtotal = $359,775

Issue Date FY: 2024 ( Subtotal = $391,755 )
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	003	7	5/21/2024	NON-COMPETING CONTINUATION	$0
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	001	7	3/7/2024	NON-COMPETING CONTINUATION	$0
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	002	7	5/13/2024	NON-COMPETING CONTINUATION	$31,980
2024	2024	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	7	2/5/2024	NON-COMPETING CONTINUATION	$359,775
														Subtotal = $391,755

Issue Date FY: 2023 ( Subtotal = $399,750 )
2023	2023	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD AVE M/C 551	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	6	4/26/2023	COMPETING CONTINUATION	$399,750
														Subtotal = $399,750

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	5	7/14/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $359,775 )
2020	2020	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	5	3/13/2020	NON-COMPETING CONTINUATION	$359,775
														Subtotal = $359,775

Issue Date FY: 2019 ( Subtotal = $359,775 )
2019	2019	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	4	4/2/2019	NON-COMPETING CONTINUATION	$359,775
														Subtotal = $359,775

Issue Date FY: 2018 ( Subtotal = $359,775 )
2018	2018	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	3	3/15/2018	NON-COMPETING CONTINUATION	$323,797
2018	2018	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	001	3	4/24/2018	NON-COMPETING CONTINUATION	$35,978
														Subtotal = $359,775

Issue Date FY: 2017 ( Subtotal = $359,775 )
2017	2017	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	001	2	7/7/2017	NON-COMPETING CONTINUATION	$35,977
2017	2017	UNIVERSITY OF ILLINOIS	809 S MARSHFIELD RM 520	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	2	2/28/2017	NON-COMPETING CONTINUATION	$323,798
														Subtotal = $359,775

Issue Date FY: 2016 ( Subtotal = $359,775 )
2016	2016	UNIVERSITY OF ILLINOIS AT CHICAGO	890 SOUTH MARSHFIELD AVENUE	CHICAGO	IL	60612	COOK	USA	Research and Training in Complementary and Integrative Health	000	1	3/3/2016	NEW	$359,775
														Subtotal = $359,775

Grand Total All Awards = $2,950,155

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Botanical derived progestins and their impact on women's health

Award Number: R01AT008824

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2016

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer